91九色视频

header-logo
Radiation Oncology Banner
Radiation Oncology

Kerns Laboratory

Location
MFRC 6009 (Lab)
MFRC 6010 (Office)

View principal investigator bio
Sara Kerns Laboratory
Kerns Lab research areas

Research Areas

The Kerns lab studies inherited genetic predisposition to development of late toxicities resulting from cancer treatment. Approaches include genome-wide association studies (GWAS), analysis of circulating biomarkers, and analysis of gene expression and epigenetic changes using biospecimens from patients undergoing treatment for cancer. The long-term goal of our research is to develop predictive models for use in the clinic to better personalize cancer treatment and survivorship care. Research conducted in the lab also aims to uncover novel biologic pathways that might be targeted to prevent or mitigate the toxic effects of cancer treatment. Much of this work is done collaboratively, through research consortia, to facilitate large-scale clinical genomic studies. Dr. Kerns is a leader in the NCI-supported and a member of the NIH-funded .

Current Members

headshot

Carson Gehl, BS

Data Specialist I

headshot

Sanchita Giri, MSc

Clinical Research Assistant II

sangiri@mcw.edu

headshot

Ayokunle Olowofela, MD, MS

Postdoctoral Researcher

aolowofela@mcw.edu

headshot

Lauren Smith, BS

Data Specialist I

91九色视频 Collaborators

headshot

William A. Hall, MD

Professor of Radiation Oncology and Surgery, School of Graduate Studies; Medical Director of Radiation Oncology, Froedtert & the 91九色视频 Clinical Cancer Center

Clinical and research interests include pancreatic cancer, prostate cancer, MRI guided radiation therapy, renal cell carcinoma and rectal cancer.

headshot

Paul Auer, PhD

Cancer Center Scholar; Director, Biostatistics Shared Resource, Cancer Center; Professor, Data Science Institute, Biostatistics

pauer@mcw.edu

headshot

Manzur Rahman Farazi, PhD

Statistical Research Scientist II, Biostatistics

mfarazi@mcw.edu

Kerns Laboratory Funding

Kerns Lab researcher
all
Current Funding
NIH/NCI R01CA291956
“Targeting angiotensin and inflammation to prevent radiotherapy-induced bladder toxicity”
(MPI: Marples, Kerns), 08/01/2024 – 07/31/2029

NIH/NCI R21CA280170
“The urinary microbiome and bladder toxicity after pelvic radiotherapy”
(MPI: Marples, Gill, Kerns), 08/01/2024 – 07/31/2026

NIH/NCI R01CA285801
“Multi-cohort validation of machine learning radiogenomic models (ML-RGx) to predict late toxicity in prostate cancer”
(MPI: Kerns, Hall, Oh), 07/01/2024 - 06/30/2029

NIH/NCI R01CA280115
“Clinical and pre-clinical investigation of extracellular vesicles as a mechanism of toxicity in the bladder of prostate cancer patients treated with radiotherapy”
(PI: Lee), 04/01/2024 – 03/31/2029
Completed Funding

NIH/NCI MP2PRT 22X016Q (subcontract to HHSN26100039)
“Evaluation of an inflammation polygenic risk score (iPRS) to predict cancer related cognitive impairment and fatigue in patients receiving chemotherapy for non-metastatic breast cancer in URCC0701 and URCC10055”
(PI: Kerns), 07/19/2022 – 12/31/2024

NIH/NCI UG1CA189961
“Biobank to Support Translational Research”
(MPIs: Janelsins, Kerns), 9/01/2021 – 8/31/2022

NIH/NCI K07CA187546
"Risk Prediction for Development of Adverse Effects Following Radiotherapy for Prostate Cancer”
(PI: Kerns), 9/18/2015 – 8/31/2021

Wilmot Cancer Institute’s Research Development Funding Program
“Elucidating the Role of the Renin-Angiotensin Pathway in Development of Hemorrhagic Radiation Cystitis”
(PIs: Kerns and Marples), 7/01/2020 – 6/30/2021

NIH/SBIR HHSN261201500043C
"Predictive Biomarkers of Adverse Reactions to Prostate Radiotherapy”
(PIs: Peterson-Roth, Kerns, Rosenstein), 9/1/2015 – 9/18/2020

DOD PC140371
"Genetic Modeling of Radiation Injury in Prostate Cancer Patients Treated With Radiotherapy”
(PIs: Rosenstein and Ostrer; UR site PI: Kerns), 9/1/2015 – 8/31/2018

Recent Publications

  • (West CML, Marignol L, Kerns SL.) Basic Clinical Radiobiology, Sixth Edition. 1 January 2025:237-249 SCOPUS ID: 2-s2.0-85212733615 01/01/2025

  • (Bouzaki A, Green D, van Herk M, Shortall J, Puri T, Kerns S, Azria D, Farcy-Jacquet MP, Chang-Claude J, Choudhury A, Dunning A, Lambrecht M, Avuzzi B, Ruysscher DD, Seibold P, Sperk E, Talbot C, Vega A, Veldeman L, Webb A, Rosenstein B, West CM, Gioscio E, Rancati T, Osorio EV, McWilliam A.) Physics and Imaging in Radiation Oncology. January 2025;33 SCOPUS ID: 2-s2.0-85215853089 01/01/2025

  • (Kullo IJ, Conomos MP, Nelson SC, Adebamowo SN, Choudhury A, Conti D, Fullerton SM, Gogarten SM, Heavner B, Hornsby WE, Kenny EE, Khan A, Khera AV, Li Y, Martin I, Mercader JM, Ng M, Raffield LM, Reiner A, Rowley R, Schaid D, Stilp A, Wiley K, Wilson R, Witte JS, Natarajan P, Polygenic Risk Methods in Diverse Populations (PRIMED) Consortium.) Am J Hum Genet. 2024 Dec 05;111(12):2594-2606 PMID: 39561770 PMCID: PMC11639095 SCOPUS ID: 2-s2.0-85210411516 11/20/2024

  • (Gehl CJ, Verhagen NB, Shaik TJ, Nimmer K, Yang X, Xing Y, Taylor BW, Nataliansyah MM, Kerns SL, Kothari AN.) J Am Coll Surg. 2024 Dec 01;239(6):539-546 PMID: 38920308 SCOPUS ID: 2-s2.0-85216036137 06/26/2024

  • (Rosenstein BS, Yamoah K, Bentzen SM, Kerns SL, McDonald JT, West CML, Vega A, Rattay T, Ricks-Santi LJ, Radiogenomics Consortium.) Int J Radiat Oncol Biol Phys. 2024 Nov 15;120(4):1107-1110 PMID: 39424580 SCOPUS ID: 2-s2.0-85206214409 10/19/2024

  • (Hall WA, Mathison AJ, DeVoe E, Tschannen M, Wendt-Andrae J, Straza M, Awan M, Puckett LL, Lawton CAF, Schultz C, Urrutia R, Kerns S, Torres-Roca JF, Li XA, Erickson B, Nevalainen MT, Zimmermann MT, Paulson E.) Int J Radiat Oncol Biol Phys. 2024 Oct 01;120(2):570-578 PMID: 38819340 SCOPUS ID: 2-s2.0-85194948255 05/31/2024

  • (Liebenberg N, McWilliam A, Kerns SL, Marshall DC, West CM.) BMJ Oncol. 2024 Jan;3(1) PMID: 39524982 PMCID: PMC11256021 11/14/2024

  • (Cui W, Plett PA, Sharma GP, Kerns S, MacVittie TJ.) Front Public Health. 2024;12:1471228 PMID: 39234079 PMCID: PMC11372479 SCOPUS ID: 2-s2.0-85203343450 09/05/2024

Publications of from the

© 2025 91九色视频.  All rights reserved.  | Terms and Privacy | Web Accessibility Statement

Non-Discrimination Statement
The 91九色视频 (91九色视频) is committed to fostering a diverse community of outstanding faculty, staff, and students, as well as ensuring equal educational opportunity, employment, and access to services, programs, and activities, without regard to an individual's race, color, national origin, religion, age, disability, sex, gender identity/expression, sexual orientation, marital status, pregnancy, predisposing genetic characteristic, or military status. Employees, students, applicants or other members of the 91九色视频 community (including but not limited to vendors, visitors, and guests) may not be subjected to harassment that is prohibited by law or treated adversely or retaliated against based upon a protected characteristic. 91九色视频’s policy as well as federal and state laws and regulations prohibit unlawful discrimination and harassment.

Notice of Compliance with Laws and Commitment to Civil Rights
The 91九色视频 is committed to full compliance with all applicable federal, state, and local laws and regulations in the pursuit of our missions. Consistent with recent federal guidance, we affirm our commitment to individual merit, fairness, and equal treatment in all aspects of academic and institutional decision-making. As part of this commitment, we are actively reviewing our policies and materials to ensure they align with federal nondiscrimination obligations.